FR2435905A1
(fr)
*
|
1978-09-13 |
1980-04-11 |
Anvar |
Nouveaux agents molluscicides derives du benzamido-2 nitro-5 thiazole
|
US4315018A
(en)
*
|
1978-12-07 |
1982-02-09 |
Rossignol Jean F |
Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
|
EP0031563B1
(fr)
*
|
1979-12-21 |
1983-09-14 |
The Wellcome Foundation Limited |
Nitrothiazolines, leur préparation et compositions pharmaceutiques les contenant
|
US5387598A
(en)
*
|
1994-04-13 |
1995-02-07 |
Rossignol; Jean-Francois |
Composition and galenic formulation suitable for combatting affections of the lower abdomen
|
US5578621A
(en)
*
|
1994-09-08 |
1996-11-26 |
Romark Lab Lc |
Benzamide derivatives
|
SI0755386T1
(en)
*
|
1994-04-13 |
2002-10-31 |
Romark Laboratories, L.C. |
Benzamide derivative, compositions containing said derivative and use thereof
|
US5968961A
(en)
|
1997-05-07 |
1999-10-19 |
Romark Laboratories, L.C. |
Pharmaceutical compositions of tizoxanide and nitazoxanide
|
MX9604483A
(es)
*
|
1994-09-08 |
1998-02-28 |
Jean-Francois Rossignol |
Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
|
US5859038A
(en)
*
|
1994-09-08 |
1999-01-12 |
Romark Laboratories, L.C. |
Method for treatment of helicobacter pylori infections
|
AU756451B2
(en)
*
|
1997-05-07 |
2003-01-16 |
Romark Laboratories, L.C. |
Pharmaceutical compositions of tizoxanide and nitazoxanide
|
CA2288003C
(fr)
*
|
1997-05-07 |
2003-10-21 |
Romark Laboratories, L.C. |
Compositions pharmaceutiques de tizoxanide et de nitazoxanide
|
US5935591A
(en)
*
|
1998-01-15 |
1999-08-10 |
Romark Laboratories, L.C. |
Method for treatment of equine protozoal myeloencephalitis with thiazolides
|
US5925622A
(en)
*
|
1998-07-13 |
1999-07-20 |
Romark Laboratories, L.C. |
Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
|
SE0102764D0
(sv)
*
|
2001-08-17 |
2001-08-17 |
Astrazeneca Ab |
Compounds
|
US7125568B2
(en)
|
2001-08-23 |
2006-10-24 |
Sung Michael T |
Lipophilic drug compositions
|
GB0226930D0
(en)
|
2002-11-19 |
2002-12-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0325402D0
(en)
*
|
2003-10-31 |
2003-12-03 |
Astrazeneca Ab |
Compounds
|
GB0327761D0
(en)
*
|
2003-11-29 |
2003-12-31 |
Astrazeneca Ab |
Compounds
|
GB0328178D0
(en)
*
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Compounds
|
KR20070007104A
(ko)
*
|
2004-02-18 |
2007-01-12 |
아스트라제네카 아베 |
화합물
|
EP2048137A1
(fr)
*
|
2004-02-18 |
2009-04-15 |
AstraZeneca AB |
Dérivés de la benzamide et leur utilisation comme activateurs de la glucokinase.
|
TW200600086A
(en)
*
|
2004-06-05 |
2006-01-01 |
Astrazeneca Ab |
Chemical compound
|
UA90864C2
(en)
*
|
2004-09-09 |
2010-06-10 |
Ромарк Лебораториз, Л.К. |
Halogenated benzamide derivatives
|
US20060194853A1
(en)
*
|
2004-10-08 |
2006-08-31 |
Rossignol Jean F |
Alkyl benzamides
|
CA2581619A1
(fr)
|
2004-10-16 |
2006-04-20 |
Astrazeneca Ab |
Procede de fabrication de composes de phenoxy benzamide
|
GB0423043D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
GB0423044D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
JP2008538362A
(ja)
*
|
2005-04-12 |
2008-10-23 |
ロマーク ラボラトリーズ エル.シー. |
タンパク質の成熟の遮断を介して疾患を処置するための方法、タンパク質ジスルフィドイソメラーゼなどの分子シャペロンの機能を阻害する、またはグリコシル化を妨害する化合物、それらを含む薬学的組成物、および治療剤を同定するためのスクリーニング方法
|
US20110059941A1
(en)
*
|
2005-05-24 |
2011-03-10 |
Peter William Rodney Caulkett |
2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
|
TW200714597A
(en)
*
|
2005-05-27 |
2007-04-16 |
Astrazeneca Ab |
Chemical compounds
|
US20110053910A1
(en)
*
|
2005-07-09 |
2011-03-03 |
Mckerrecher Darren |
2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
|
EP2027113A1
(fr)
*
|
2005-07-09 |
2009-02-25 |
AstraZeneca AB |
Dérivés d'hétéroaryl benzamide utilisés en tant qu'activateurs de la glk dans le traitement du diabète
|
BRPI0622262A2
(pt)
*
|
2005-07-09 |
2011-08-09 |
Astrazeneca Ab |
composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
|
US9202182B2
(en)
*
|
2005-08-11 |
2015-12-01 |
International Business Machines Corporation |
Method and system for analyzing business architecture
|
TW200738621A
(en)
*
|
2005-11-28 |
2007-10-16 |
Astrazeneca Ab |
Chemical process
|
ES2422556T3
(es)
*
|
2006-01-09 |
2013-09-12 |
Romark Lab Lc |
Tratamiento de hepatitis vírica
|
US7678791B2
(en)
*
|
2006-07-12 |
2010-03-16 |
Cumbre Ip Ventures, L.P. |
Nitroheteroaryl-containing rifamycin derivatives
|
CN100465169C
(zh)
*
|
2006-08-02 |
2009-03-04 |
杭州欣阳三友精细化工有限公司 |
硝唑尼特的制备方法
|
TW200825063A
(en)
*
|
2006-10-23 |
2008-06-16 |
Astrazeneca Ab |
Chemical compounds
|
TW200825060A
(en)
*
|
2006-10-26 |
2008-06-16 |
Astrazeneca Ab |
Chemical compounds
|
WO2008075073A1
(fr)
*
|
2006-12-21 |
2008-06-26 |
Astrazeneca Ab |
Nouveau composé cristallin utile en tant qu'activateur de glk
|
CN101007792B
(zh)
*
|
2007-01-31 |
2010-05-26 |
浙江大学 |
一种合成硝基噻唑苯酰胺化合物的方法
|
BRPI0815057B8
(pt)
|
2007-08-03 |
2021-05-25 |
Romark Laboratories Lc |
composto, composição farmacêutica, e, uso de um composto
|
WO2010015849A2
(fr)
*
|
2008-08-04 |
2010-02-11 |
Astrazeneca Ab |
Agents thérapeutiques 414
|
EA021377B9
(ru)
|
2008-12-09 |
2015-09-30 |
Джилид Сайэнс, Инк. |
Модуляторы толл-подобных рецепторов
|
CA2752233C
(fr)
|
2009-02-13 |
2017-01-03 |
Romark Laboratories L.C. |
Formulations pharmaceutiques de nitazoxanide a liberation controlee
|
GB0902406D0
(en)
*
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Crystalline polymorphic form
|
GB0902434D0
(en)
*
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Chemical process
|
AR076221A1
(es)
*
|
2009-04-09 |
2011-05-26 |
Astrazeneca Ab |
Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
|
AR076220A1
(es)
|
2009-04-09 |
2011-05-26 |
Astrazeneca Ab |
Derivados de pirazol [4,5 - e] pirimidina
|
JP5918124B2
(ja)
*
|
2009-05-12 |
2016-05-18 |
ロマーク ラボラトリーズ エル.シー. |
ハロアルキルヘテロアリールベンズアミド化合物
|
BRPI1014322A2
(pt)
|
2009-06-26 |
2015-08-25 |
Romark Lab Lc |
Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
|
CN101602744B
(zh)
*
|
2009-06-30 |
2011-06-01 |
青岛康地恩药业有限公司 |
一种硝唑尼特的制备方法
|
WO2013110975A1
(fr)
|
2012-01-27 |
2013-08-01 |
Siegfried Rhein S.A. De C.V. |
Composition de nitazoxanide améliorée et son procédé de préparation
|
WO2014049397A1
(fr)
|
2012-09-27 |
2014-04-03 |
Siegfried Rhein S.A. De C.V. |
Composition synergique de nitazoxanide et de mébendazole, procédés de préparation correspondants et utilisation de cette composition dans le traitement de la parasitose humaine
|
WO2014205414A1
(fr)
*
|
2013-06-21 |
2014-12-24 |
The Regents Of The University Of California |
Potentiel thérapeutique étendu dans des antimicrobiens à nitrohétéroaryle
|
TWI806081B
(zh)
|
2014-07-11 |
2023-06-21 |
美商基利科學股份有限公司 |
用於治療HIV之toll樣受體調節劑
|
UY36298A
(es)
|
2014-09-16 |
2016-04-29 |
Gilead Science Inc |
Formas sólidas de un modulador del receptor tipo toll
|
BR112017009651A2
(pt)
|
2014-11-11 |
2017-12-19 |
Romark Laboratories Lc |
composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.
|
CN105175352A
(zh)
*
|
2015-10-27 |
2015-12-23 |
杭州澳医保灵药业有限公司 |
一种硝唑尼特的制备方法
|
CN106831640A
(zh)
*
|
2015-12-03 |
2017-06-13 |
江苏正大丰海制药有限公司 |
一种硝唑尼特晶体的制备方法
|
EP3677282A1
(fr)
|
2016-03-31 |
2020-07-08 |
Romark Laboratories, L.C. |
Composés de thiazolide pour traiter des infections virales
|
HUE060671T2
(hu)
|
2016-04-11 |
2023-04-28 |
Genfit |
Eljárás fibrotikus betegségek kezelésére
|
SG11201906041QA
(en)
|
2017-01-27 |
2019-08-27 |
Genfit |
Pharmaceutical compositions for combination therapy
|
US11173149B2
(en)
|
2017-04-18 |
2021-11-16 |
Romark Laboratories L.C. |
Inhibition of protein disulfide-isomerase A3
|
BR112021020496A2
(pt)
|
2019-04-12 |
2021-12-07 |
Genfit |
Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo
|
JP2023500278A
(ja)
|
2019-10-28 |
2023-01-05 |
ジェンフィット |
抗酸化性質を有する併用療法
|
JP2023537237A
(ja)
|
2020-07-20 |
2023-08-31 |
ロマーク ラボラトリーズ,リミティド カンパニー |
チゾキサニドおよび2-ヒドロキシ-n-(5-クロロ-1,3-チアゾル-2-イル)ベンズアミド(rm-4848)とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびn-メチルピペラジンの結晶塩
|
CN116367892A
(zh)
|
2020-08-24 |
2023-06-30 |
罗马克实验室有限公司 |
噻唑化物抗冠状病毒的用途
|
CN114044761B
(zh)
*
|
2021-02-24 |
2022-05-17 |
成都贝诺科成生物科技有限公司 |
一种新的硝基噻唑衍生物及其应用
|
CN115197164A
(zh)
*
|
2021-04-12 |
2022-10-18 |
杜心赟 |
新型噻唑类化合物及其制备方法和用途
|
WO2023058046A1
(fr)
|
2021-10-05 |
2023-04-13 |
Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) |
Procédé amélioré pour préparer du nitazoxanide et de ses intermédiaires
|
WO2023198095A1
(fr)
*
|
2022-04-12 |
2023-10-19 |
成都贝诺科成生物科技有限公司 |
Utilisation d'un dérivé de nitrothiazole dans la préparation d'un bactériostatique pour inhiber helicobacter pylori
|